Prostate Cancer: 2020 Year in Review
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Urocross shows sustained benefit through 24 months post-removal
3
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
4
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
5